IDH1-R132H monoclonal antibody (HMAb-1)

Anti-human isocitrate dehydrogenase 1 (IDH1) – R132H antibody binds to IDH1-mutated protein, but does not bind the wild-type IDH1 protein. Mutations in the IDH 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation IDH1-R132H. IDH1-R132H can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis, and as a prognostic marker for gliomas and secondary glioblastoma multiforme.

Isocitrate dehydrogenase 1 (NADP+), soluble is an enzyme that in humans is encoded by the IDH1 gene. Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. IDH1 is one of three isocitrate dehydrogenase isozymes, the other two being IDH2 and IDH3. IDH1 mutations are heterozygous, typically involving an amino acid substitution in the active site of the enzyme in codon 132. The mutation results in a loss of normal enzymatic function and the abnormal production of 2-hydroxyglutarate (2-HG). Mutations in IDH1 are often the first hit in the development of diffuse gliomas, suggesting IDH1 mutations as key events in the formation of these brain tumors.